Egetis Therapeutics AB (publ)
STO:EGTX
Egetis Therapeutics AB (publ)
STO:EGTX
Price:
5.3
SEK
-6.69%
Market Closed
Market Cap:
kr2.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Egetis Therapeutics AB (publ)
STO:EGTX
|
SE |
|
Z
|
Zhihu Inc
HKEX:2390
|
CN |
|
Dongguan Aohai Technology Co Ltd
SZSE:002993
|
CN |
Income Statement
Earnings Waterfall
Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ)
Income Statement
Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ)
Currency: SEK
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
0
|
18
|
0
|
0
|
0
|
0
|
|
| Revenue |
68
N/A
|
65
-5%
|
41
-37%
|
44
+9%
|
36
-18%
|
40
+10%
|
38
-4%
|
42
+9%
|
21
-49%
|
20
-5%
|
23
+13%
|
22
-2%
|
24
+6%
|
31
+30%
|
58
+88%
|
74
+28%
|
82
+11%
|
79
-3%
|
46
-42%
|
47
+2%
|
47
+1%
|
55
+17%
|
62
+13%
|
|
| Gross Profit | ||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
(2)
|
(3)
|
(5)
|
(7)
|
(8)
|
(8)
|
(8)
|
(7)
|
(6)
|
(7)
|
(6)
|
(8)
|
(11)
|
(9)
|
(11)
|
(12)
|
(12)
|
(19)
|
(29)
|
(39)
|
(50)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
39
N/A
|
5
-86%
|
28
+438%
|
33
+15%
|
30
-7%
|
33
+9%
|
13
-60%
|
13
-5%
|
16
+30%
|
16
-4%
|
17
+9%
|
23
+35%
|
47
+103%
|
65
+40%
|
72
+9%
|
68
-5%
|
35
-49%
|
28
-18%
|
19
-33%
|
17
-12%
|
12
-26%
|
|
| Operating Income | ||||||||||||||||||||||||
| Operating Expenses |
(248)
|
(234)
|
(216)
|
(238)
|
(181)
|
(178)
|
(135)
|
(149)
|
(130)
|
(165)
|
(213)
|
(259)
|
(306)
|
(343)
|
(367)
|
(334)
|
(335)
|
(326)
|
(356)
|
(354)
|
(348)
|
(341)
|
(352)
|
|
| Selling, General & Administrative |
(29)
|
(29)
|
(22)
|
(29)
|
(24)
|
(26)
|
(30)
|
(32)
|
(36)
|
(41)
|
(52)
|
(59)
|
(65)
|
(75)
|
(84)
|
(100)
|
(130)
|
(163)
|
(215)
|
(216)
|
(209)
|
(202)
|
(201)
|
|
| Research & Development |
(208)
|
(194)
|
(183)
|
(194)
|
(142)
|
(136)
|
(89)
|
(98)
|
(75)
|
(102)
|
(136)
|
(164)
|
(183)
|
(193)
|
(194)
|
(156)
|
(155)
|
(136)
|
(146)
|
(144)
|
(140)
|
(141)
|
(158)
|
|
| Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(2)
|
(3)
|
(3)
|
(4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
(11)
|
(11)
|
(10)
|
(15)
|
(14)
|
(14)
|
(14)
|
(16)
|
(17)
|
(19)
|
(22)
|
(33)
|
(55)
|
(71)
|
(86)
|
(78)
|
(49)
|
(26)
|
5
|
6
|
1
|
1
|
7
|
|
| Operating Income |
(180)
N/A
|
(169)
+6%
|
(177)
-5%
|
(197)
-11%
|
(150)
+24%
|
(145)
+3%
|
(105)
+28%
|
(116)
-10%
|
(117)
-1%
|
(152)
-31%
|
(197)
-29%
|
(244)
-24%
|
(289)
-19%
|
(320)
-11%
|
(320)
0%
|
(269)
+16%
|
(264)
+2%
|
(258)
+2%
|
(322)
-25%
|
(326)
-1%
|
(329)
-1%
|
(324)
+1%
|
(340)
-5%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||
| Interest Income Expense |
3
|
(0)
|
(1)
|
(0)
|
(3)
|
(1)
|
1
|
5
|
7
|
8
|
3
|
4
|
3
|
2
|
(4)
|
(4)
|
(9)
|
(13)
|
(17)
|
(15)
|
(8)
|
(7)
|
(9)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
(3)
|
(6)
|
2
|
1
|
(4)
|
10
|
(0)
|
(1)
|
7
|
|
| Pre-Tax Income |
(177)
N/A
|
(170)
+4%
|
(178)
-5%
|
(197)
-11%
|
(153)
+23%
|
(147)
+4%
|
(105)
+29%
|
(110)
-6%
|
(109)
+1%
|
(144)
-32%
|
(194)
-34%
|
(240)
-24%
|
(286)
-19%
|
(319)
-11%
|
(327)
-3%
|
(278)
+15%
|
(271)
+3%
|
(271)
N/A
|
(343)
-27%
|
(331)
+4%
|
(337)
-2%
|
(333)
+1%
|
(342)
-3%
|
|
| Net Income | ||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(177)
|
(170)
|
(178)
|
(197)
|
(153)
|
(147)
|
(105)
|
(110)
|
(109)
|
(144)
|
(194)
|
(240)
|
(286)
|
(319)
|
(327)
|
(278)
|
(271)
|
(271)
|
(344)
|
(331)
|
(337)
|
(333)
|
(343)
|
|
| Net Income (Common) |
(177)
N/A
|
(170)
+4%
|
(178)
-5%
|
(197)
-11%
|
(153)
+23%
|
(147)
+4%
|
(105)
+29%
|
(110)
-6%
|
(109)
+1%
|
(144)
-32%
|
(194)
-34%
|
(240)
-24%
|
(286)
-19%
|
(319)
-11%
|
(327)
-3%
|
(303)
+7%
|
(296)
+3%
|
(296)
N/A
|
(344)
-16%
|
(332)
+4%
|
(337)
-2%
|
(333)
+1%
|
(343)
-3%
|
|
| EPS (Diluted) |
-3.25
N/A
|
-3.12
+4%
|
-2.42
+22%
|
-1.09
+55%
|
-0.84
+23%
|
-0.81
+4%
|
-0.58
+28%
|
-0.61
-5%
|
-0.55
+10%
|
-0.67
-22%
|
-1
-49%
|
-1
N/A
|
-1.14
-14%
|
-1.27
-11%
|
-1.27
N/A
|
-1.34
-6%
|
-1.01
+25%
|
-1.01
N/A
|
-1.12
-11%
|
-0.92
+18%
|
-0.93
-1%
|
-0.94
-1%
|
-0.93
+1%
|
|
Switch to:
Switch to:
See Also
Discover More
